Hepatitis C virus-related B cell subtypes in non Hodgkin's lymphoma

Table 1 Clinical and biological characteristics of 24 hepatitis C virus patients with low and high grade B cell-non Hodgkin’s lymphoma

	Sex	Age(yr)	HCV RNA log10 (UI/mL)	HCVgenotype	Duration of HCV-infection (mo)	Ishak(grading)	Ishak(staging)	Type of lymphoma	Stage	Extranodal	Cryoglobulin	Bcl2/Bcl6
1	F	70	5.90	2a/2c	21	4	0	Marginal extranodal (MALT)	IV	Orbit/BM	Positive	+/-
2	F	69	5.40	2a	19	12	6	Marginal extranodal (MALT)	IV	Parotid/BM	Positive	-/-
3	F	64	nd	2	25	nd	nd	Marginal extranodal (MALT)	IV	Orbit/BM	Positive	na
4	M	36	nd	2	7	6	1	Splenic marginal	IV	Spleen/BM	Negative	-/-
5	F	72	6.00	1b	22	8	2	Splenic marginal	III	Spleen	Negative	-/-
6	F	65	nd	2a/2c	nd	nd	nd	Splenic marginal	IV	Spleen/BM	Negative	-/-
7	F	70	5.90	2	nd	8	1	Marginal nodal	IV	BM	Positive	-/-
8	F	55	5.07	2a/2c	31	17	6	Follicular lymphoma	III	None	na	+/+
9	M	67	6.80	2a	30	6	0	Follicular lymphoma	IV	Liver/BM	Negative	+/-
10	F	59	nd	2	20	16	6	Follicular lymphoma	III	None	Negative	+/+
11	F	78	nd	2a	30	nd	nd	Lymphoplasmocytoid lymphoma	IV	BM	Positive	na
12	M	61	nd	1b	18	5	2	DLBCL	IV	BM	na	na
13	M	29	7.80	1a	4	6	0	DLBCL	II	None	Negative	+/+
14	M	66	6.70	1b	nd	12	6	DLBCL		Liver, Lung	na	na
15	M	62	6.90	1a	10	nd	nd	DLBCL	IV	BM	na	na
16	M	56	5.1	1b	nd	nd	nd	DLBCL	IV	BM	na	na
17	F	55	5.4	1b	nd	nd	nd	DLBCL	IV	Liver	na	na
18	F	59	6.4	1a/1b	nd	nd	nd	DLBCL	IV	Lung/BM	na	+/+
19	M	65	5.8	1b	11	10	2	DLBCL	IV	Lung	Negative	+/+
20	M	46	nd	1b	6	8	1	DLBCL	IV	Liver	Negative	+/+
21	M	51	6.3	1b	15	10	2	DLBCL	IV	Lung/BM	Negative	-/-
22	M	49	5.9	3	15	nd	nd	DLBCL	IV	Gastric	Negative	-/-
23	M	78	6.2	2a/2c	19	10	1	DLBCL	III	None	Negative	+/+
24	F	74	5.0	1	16	10	4	DLBCL	IV	Palatine Tonsil/BM	Negative	-/-

DLBCL: Diffuse large B cells lymphoma; nd: Not determined; Extranodal: Extranodal involvement; BM: Bone marrow; na: Not available; MALT: Mucosal associated lymphoid tissue; HCV: Hepatitis C virus.

Table 2 Comparison of biological, virological and clinical characteristics of hepatitis C virus-related low vs high grade B cell-non Hodgkin’s lymphoma

	DLBCL (n = 13)	Indolent B-NHL (n = 11)	95% CI	P value
Age ( yr)1	57 ± 12	64 ± 11	-16.8 to 2.8	0.153
Sex (M/F)	10/3	2/9	-	0.014
Duration of HCV infection (yr)1	12 ± 5	22 ± 7	-15.1 to -4.9	< 0.001
ALT value (UI/L)1	58 ± 40	40 ± 27	-11.5 to 47.5	0.219
Genotype 1/not 1	10/3	2/9	-	0.014
HCVRNA log10 (UI/mL)1	6.1 ± 0.6	5.8 ± 0.3	-0.11 to 0.71	0.147
Ishak (grading)1	8.4 ± 2.1	9.3 ± 5.0	-4.05 to 2.25	0.560
Ishak (staging)1	1.5 ± 1.2	2.75 ± 2.7	-2.97 to 0.47	0.146

Means ± SD; HCV: Hepatitis C virus; B-NHL: B cell-Non Hodgkin’s lymphoma; DLBCL: Diffuse large B cells lymphoma; CI: Confidence interval.

Table 3 Results of antiviral treatment in patients with low grade B cell-non Hodgkin’s lymphoma

	Sex	Age (yr)	Histology	Stage	HCVRNA log10 (UI/mL)	Genotype	Staging (Ishak)	Treatment	Treatment duration (mo)	Response to treatment	Remission lymphoma
1	F	70	Marginal extranodal	IV	5.9	2a/2c	0	Peg 180 μg/wk + RBV 800 mg/d	6	SVR	Complete hematological response
2	F	69	Marginal extranodal	IV	5.4	2a	6	Peg 180 μg/wk + RBV 800 mg/d	6	SVR	Complete hematological response
3	F	64	Marginal extranodal	IV	5.6	1b	nd	Peg 180 μg/wk + RBV 1000 mg/d	12	Relapser	Progressive disease
4	M	36	Marginal splenic	IV	5.5	2	1	Peg 180 μg/wk + RBV 800 mg/d	6	SVR	Partial response
5	F	72	Marginal splenic	III	6.0	1b	2	Peg 180 μg/wk + RBV 1000 mg/d	12	SVR	Partial response
6	F	65	Marginal splenic	IV	5.6	2a/2c	nd	Peg 180 μg/wk + RBV 1200 mg/d	6	SVR	Complete hematological response
7	F	70	Marginal nodal	IV	5.9	2	2	Peg 180 μg/wk + RBV 800 mg/d	6	SVR	Complete hematological response
8	F	55	Follicular lymphoma	III	5.0	2a/2c	6	Peg 180 μg/wk + RBV 800 mg/d	6	Relapser	Progressive disease
9	M	67	Follicular lymphoma	IV	6.8	2a	0	Peg 180 μg/wk + RBV 800 mg/d	6	SVR	Complete hematological response

MU: Million of units; RBV: Ribavirin; SVR: Sustained virological response.